GLP-1 & Incretin Multi-Agonists · Peptide API · research grade also available

Tirzepatide API Supplier from India

CAS 2023788-19-2 · 4813.53 g/mol · COA with every batch

Tirzepatide (CAS 2023788-19-2) is a 39-amino-acid acylated peptide that acts as a dual GIP and GLP-1 receptor agonist, approved as an active ingredient by the US FDA and EMA. Winhycare Pharma supplies Tirzepatide as an API to licensed pharmaceutical manufacturers and developers and, separately, as a research-grade peptide for laboratory research use only, at >99% purity with QC documentation. Research-grade material is not for human or veterinary use.

Request API pricing & COA WhatsApp Winhycare Pharma

By Kareem Ahmed Basha, Director & Chief Scientific Officer · Reviewed by Nisar Mohammed, Founder & Managing Director · Updated

Need research-grade Tirzepatide for laboratory work? Request a research quote (research use only). See all five peptide APIs.

Specification card for Tirzepatide API: CAS 2023788-19-2, GIP / GLP-1 dual receptor agonist
CAS Number
2023788-19-2
Molecular Formula
C225H348N48O68
Molecular Weight
4813.53 g/mol
Drug Class
GIP / GLP-1 dual receptor agonist

What is Tirzepatide?

Tirzepatide is a long-acting dual incretin receptor agonist: a single 39-amino-acid peptide engineered to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. The backbone carries two α-aminoisobutyric acid (Aib) substitutions and a C-terminal amide, and is acylated at a lysine residue with a C20 fatty di-acid through a γGlu-2×OEG linker, conferring strong albumin binding, resistance to DPP-4 degradation and an extended half-life.

With CAS number 2023788-19-2, molecular formula C225H348N48O68 and a molecular weight of approximately 4813.53 g/mol, tirzepatide is typically handled as a lyophilised powder. It is approved as an active ingredient by the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and by the EMA (2022 for type 2 diabetes).

How Tirzepatide Is Produced & Characterised

Tirzepatide is a synthetically demanding acylated peptide: the 39-mer length, the two Aib residues and the C20 fatty di-acid conjugation all create opportunities for deletion sequences, diastereomers and incomplete acylation. In industry practice, peptides of this class are produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled lipid side-chain conjugation, followed by preparative dynamic axial compression (DAC) HPLC purification that isolates the target sequence from closely related impurities. The purified material is typically lyophilised to a stable, uniform powder.

Characterisation generally combines UPLC/HPLC for purity determination with LC-MS to confirm the sequence and profile minor structural variants. Counter-ion (acetate) content, water content, residual solvents and peptide content are commonly measured so the molecule's identity, strength and impurity profile are fully described.

Regulatory & Approval Context

Tirzepatide is approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management; 2024 for moderate to severe obstructive sleep apnoea in adults with obesity; 2026 for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk) and the EMA (2022 for type 2 diabetes). As an approved molecule, its chemistry, manufacturing and controls (CMC) are documented within regulatory frameworks such as the CTD, and analytical and stability data are characterised to support the molecule's regulated status.

Research-grade tirzepatide supplied for laboratory use is not the approved medicinal product.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Tirzepatide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Tirzepatide in their country.

Research-grade material: research use only. Research-grade Tirzepatide is supplied for laboratory research only, not for human or veterinary use; API-grade material for pharmaceutical manufacturers is quoted separately with its documentation. We do not provide dosing or usage advice. Approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management; 2024 for moderate to severe obstructive sleep apnoea in adults with obesity; 2026 for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk) and the EMA (2022 for type 2 diabetes).

Tirzepatide API: Specifications

Compound Tirzepatide
CAS Number 2023788-19-2
Molecular Formula C225H348N48O68
Molecular Weight 4813.53 g/mol
Sequence 39 amino acids, acylated (C20 di-acid side chain), C-terminal amide
Drug Class GIP / GLP-1 dual receptor agonist
Appearance White to off-white lyophilised powder
Purity >99% (research grade)
Typical synthesis route Fmoc SPPS + DAC prep-HPLC purification
Regulatory Status Approved active ingredient (US FDA 2022/2023; EMA 2022)
Form Lyophilised powder
Storage Store at -20°C, protected from light & moisture
Intended use Research use only (RUO)

API supplied for B2B pharmaceutical manufacturing and R&D. Tirzepatide is also supplied for research use only, not for human or veterinary use. Regulatory status: Approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management; 2024 for moderate to severe obstructive sleep apnoea in adults with obesity; 2026 for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk) and the EMA (2022 for type 2 diabetes).

Research guides

Articles in the Peptide Research Library that cover Tirzepatide.

  • Tirzepatide: research overviewTirzepatide is a 39-amino-acid peptide based on the GIP sequence that activates both the GIP and GLP-1 receptors. Two Aib residues resist DPP-4, and a C20 fatty di-acid on lysine 20 binds albumin, giving an elimination half-life of about 5 days. The SURPASS and SURMOUNT phase 3 programmes support its approvals.
  • Eloralintide: what it is, how it works and what studies have foundEloralintide (LY3841136) is an investigational 37-amino-acid acylated amylin analogue that preferentially activates the amylin-1 receptor (AMY1R) over the calcitonin receptor. Peer-reviewed phase 1 and 48-week phase 2 data have been published, and the ENLIGHTEN phase 3 programme began in late 2025. It is not approved anywhere.
  • FDA-approved peptide drugs: a list by INN, approval year, target and lengthReviews published in 2021 and 2022 put the number of peptide drugs approved worldwide at more than 80. The tables below list 55 FDA-approved peptides by INN, from oxytocin and glucagon to the 2026 approvals rusfertide, icotrokinra, enlicitide and navepegritide, with first Drugs@FDA approval year, target and length. Data cut-off: 26 October 2026.
  • GLP-1 receptor agonists explained: how they work, the full list, and where research is headingGLP-1 receptor agonists are peptides, and now one small molecule, that activate the receptor for the gut hormone glucagon-like peptide-1. The receptor raises cAMP in beta cells, increasing insulin secretion only when glucose is high, while also suppressing glucagon, slowing gastric emptying and reducing food intake. Dual and triple agonists add GIP or glucagon receptor activity.
  • HPLC method validation under ICH Q2(R2) and Q14: a practical guide for peptide purity and assay methodsICH Q2(R2), adopted on 1 November 2023 and in effect in the EU since 14 June 2024, sets how an HPLC method is shown fit for purpose. A peptide purity or assay method is validated for specificity, reportable range and response, accuracy, precision and, for impurities, quantitation limit, with robustness studied during development under ICH Q14.
  • What is ICH Q11? Starting materials, control strategy and Q6A/Q6B specifications for peptide drug substancesICH Q11 is the ICH guideline on developing and manufacturing drug substances, adopted on 1 May 2012. It covers process development, starting material selection, control strategy and how this is presented in CTD sections 3.2.S.2.2–3.2.S.2.6. ICH Q6A and Q6B cover specifications, but only partly fit synthetic peptides, so EMA's 2025 peptide guideline fills the gaps.
  • Mazdutide: what it is, how it works and what studies have foundMazdutide (IBI362, LY3305677) is a 34-amino-acid acylated oxyntomodulin analogue that activates both the GLP-1 receptor and the glucagon receptor. China's NMPA approved it for chronic weight management in June 2025 and for glycaemic control in type 2 diabetes in September 2025. Elsewhere it remains investigational.
  • Peptide mass spectrometry: how ESI, MALDI, MS/MS and LC-MS confirm a peptide's identityMass spectrometry identifies a peptide by measuring the mass-to-charge ratio of its ions. ESI or MALDI turns the peptide into gas-phase ions, the intact mass is compared with the theoretical monoisotopic or average mass, and MS/MS fragments the backbone into b and y (or c and z) ions that read out the sequence.
  • Peptide modifications for stability and half-life: lipidation, PEGylation, Aib, cyclisation and fusionNative peptides are cleared in minutes. Modifications fix that in two ways: blocking proteolysis, with non-natural residues such as Aib, D-amino acids, cyclisation and terminal capping; and slowing renal clearance, with fatty acid acylation or PEGylation that enlarge the molecule or bind it to albumin.
  • Peptide synthesis: how peptides are made, from the first resin bead to a purified kilogramPeptide synthesis builds a chain of amino acids in a controlled order. Most peptides are made by solid-phase peptide synthesis (SPPS), where the chain grows on a resin through repeated deprotection and coupling cycles, then is cleaved, purified by preparative chromatography and isolated, usually by lyophilization.
  • Retatrutide: what it is, how it works and what studies have foundRetatrutide (LY3437943) is an investigational 39-amino-acid peptide that activates the GIP, GLP-1 and glucagon receptors. It carries Aib at positions 2 and 20, α-methyl-leucine at 13 and a C20 fatty di-acid on lysine 17, giving a half-life of about 6 days. Phase 3 TRIUMPH results were published in 2026; it is not approved anywhere.
  • Retatrutide vs tirzepatide: how the triple and dual agonists compareRetatrutide is an investigational 39-residue peptide that activates GIP, GLP-1 and glucagon receptors; tirzepatide is an approved 39-residue GIP and GLP-1 receptor agonist. They share 30 of 39 positions and a C20 di-acid, but differ in linker, acylation site and receptor profile. No head-to-head result has been published; TRIUMPH-5 is ongoing.
  • Semaglutide: what it is, how it works and what studies have foundSemaglutide is a 31-amino-acid analogue of human GLP-1(7–37) that activates the GLP-1 receptor. An Aib substitution at position 8 blocks DPP-4 cleavage, and a C18 fatty di-acid on lysine 26 binds albumin, giving an elimination half-life of about one week. Phase 3 programmes (SUSTAIN, PIONEER, STEP, SELECT) underpin its approvals.
  • Semaglutide vs tirzepatide vs liraglutide: how the three peptide APIs compareHow semaglutide, tirzepatide and liraglutide APIs differ: backbone, length, lipid chain, receptors, half-life basis, molecular weight, CAS and approval.
  • Survodutide: what it is, how it works and what studies have foundSurvodutide (BI 456906) is an investigational 29-amino-acid acylated peptide that activates both the glucagon receptor and the GLP-1 receptor. It has completed phase 3 obesity trials (SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD) and is in phase 3 for MASH. No regulator had approved it as of October 2026.
  • What is a peptide? Definition, types, functions and how peptides are madeA peptide is a chain of amino acids joined by amide links called peptide bonds. IUPAC calls chains of fewer than about 10 to 20 residues oligopeptides and longer chains polypeptides. Many hormones, such as oxytocin and GLP-1, are peptides, and more than 80 peptide drugs have reached the market.

Buyer guides

Regulatory and technical reading for teams qualifying an Indian peptide API source.

Tirzepatide API: Frequently Asked Questions

What is Tirzepatide?

Tirzepatide is a synthetic, long-acting peptide that acts as a dual agonist at both the GIP and GLP-1 receptors. It is a single 39-amino-acid chain acylated with a C20 fatty di-acid side chain and carrying a C-terminal amide.

What is its CAS number and molecular weight?

Tirzepatide's CAS number is 2023788-19-2, its molecular formula is C225H348N48O68, and its molecular weight is approximately 4813.53 g/mol.

Is Tirzepatide approved?

Yes. Tirzepatide is approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes, 2023 for chronic weight management, 2024 for moderate to severe obstructive sleep apnoea in adults with obesity and 2026 for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk) and the EMA (2022 for type 2 diabetes).

What class of peptide is Tirzepatide?

Tirzepatide belongs to the GLP-1 and incretin multi-agonist class. Specifically, it is a GIP / GLP-1 dual receptor agonist: a single peptide that activates two incretin receptors.

What is Tirzepatide being studied or used for?

Tirzepatide is indicated for type 2 diabetes and chronic weight management (obesity), reflecting its dual incretin receptor activity on glucose regulation and body weight.

How is Tirzepatide produced and characterised?

Peptides of this class are generally produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled lipid side-chain conjugation, followed by preparative HPLC purification and lyophilisation. Identity and purity are typically confirmed by UPLC/HPLC and LC-MS impurity profiling.

Do you supply Tirzepatide as an API?

Yes. Winhycare Pharma supplies Tirzepatide API to licensed pharmaceutical manufacturers and developers, with QC documentation. Tell us the quantity and the documentation your quality and regulatory teams need. Research-grade Tirzepatide is supplied separately, for laboratory research use only.

Is Tirzepatide sold for human use?

No. Research-grade Tirzepatide is supplied for research use only (RUO), for laboratory research and development. It is not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics. Although Tirzepatide is an approved active ingredient in some markets, research-grade material is not a medicinal product.

What purity is Tirzepatide supplied at?

Research-grade Tirzepatide is supplied at high purity (>99%), produced under stringent quality control and accompanied by QC documentation. State any specific purity or documentation requirement in your enquiry.

How do I order Tirzepatide for research?

Send an enquiry with the quantity, purity, documentation you need and the destination country, and our team will reply with dedicated technical assistance. The buyer is responsible for complying with the import and use regulations for Tirzepatide in their country.

How much does Tirzepatide API cost?

There is no public price list for Tirzepatide API. The price depends on the quantity, the purity specification, the documentation package and the packaging, so we quote per programme. Send your specification and target volume to receive pricing and a Certificate of Analysis.

Sources

  1. Tirzepatide: substance record, CAS Common Chemistry
  2. Tirzepatide: compound record, PubChem, NCBI
  3. Tirzepatide, Wikipedia

Related Peptides

GLP-1 & Incretin Multi-Agonists

Semaglutide API

CAS 910463-68-2

 GLP-1 & Incretin Multi-Agonists

Retatrutide API

CAS 2381089-83-2

 Amylin & Co-Agonists

Cagrilintide API

CAS 1415456-99-3

 GLP-1 & Incretin Multi-Agonists

Mazdutide

CAS 2259884-03-0

Source Tirzepatide API from Winhycare Pharma

Request pricing, a Certificate of Analysis and the documentation your quality and regulatory teams need. Bulk quantities available.

Request a quote
WhatsApp Us Get a Quote